By Sahithya K · Reviewed by Divya Chandradhara · Published 29 October 2026

The New Drugs and Clinical Trials Rules, 2019 (the NDCT Rules) govern clinical trials, bioavailability and bioequivalence studies, new drugs and investigational new drugs in India, together with the ethics committees that oversee them. They were notified by the Central Government on 19 March 2019 and are administered by the Central Licencing Authority.

What the Rules cover, and who they bind

The Rules were notified as G.S.R. 227(E), dated 19 March 2019, under section 12 and section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), after consultation with the Drugs Technical Advisory Board. The Central Drugs Standard Control Organisation publishes the gazette text of the Rules.

Under rule 1(3) they apply to all new drugs, investigational new drugs for human use, clinical trials, bioequivalence studies, bioavailability studies and Ethics Committees. Under rule 1(2) they took effect on publication in the Official Gazette, except Chapter IV, which followed after one hundred and eighty days.

The preamble records the Supreme Court of India’s observation, in Writ Petition (Civil) No. 33/2012, that new clinical trial rules should be finalised urgently. The Rules were amended by G.S.R. 21(E) of 18 January 2022 and again in 2026.

How the Rules are organised

The Rules are divided into chapters, and the obligations that fall on a sponsor sit in the first seven. Later chapters deal with the manufacture and import of new drugs and investigational new drugs used in trials. The instrument also carries Schedules, and three are referred to repeatedly: the Third Schedule for ethics committee registration documents, the Sixth Schedule for fees and the Seventh Schedule for the loss-of-wages basis used in compensation.

Table 1. How the Rules are organised

ChapterSubjectRulesWho it matters to
IPreliminary1 to 2Everyone
IIAuthorities and officers3 to 5Everyone
IIIEthics committee for clinical trial, bioavailability and bioequivalence study6 to 14Sites and ethics committees
IVEthics committee for biomedical and health research15 to 18Academic and research institutions
VClinical trial, bioavailability and bioequivalence study of new drugs and investigational new drugs19 to 38Sponsors
VICompensation39 to 43Sponsors
VIIBioavailability and bioequivalence study centre44 to 51Study centres

Chapters VIII onward deal with the manufacture and import of new drugs and investigational new drugs for use in trials, and with the Schedules.

The ethics committee

No clinical trial can start at a site until a registered Ethics Committee has approved the protocol. The committee is a legal gate, not a formality, and Chapter III governs it.

Who sits on it

An Ethics Committee must have at least seven members, drawn from medical, non-medical, scientific and non-scientific areas, under rule 7. They must include at least one lay person, one woman member, one legal expert and one independent member from a related field, such as a social scientist, a non-governmental voluntary agency representative, a philosopher, an ethicist or a theologian.

At least fifty percent of members must be unaffiliated with the host institute or organisation. The Chairperson is appointed from the unaffiliated members and the Member Secretary from the affiliated ones. Medical scientists and clinicians need at least a postgraduate qualification in their specialisation.

Every member must complete the training and development programmes specified by the Central Licencing Authority, and a member who has not is disqualified. A member with a conflict of interest takes no part in oversight of that protocol: all members sign a declaration, a conflicted member may withdraw in writing to the Chairperson and the conflict is minuted.

Registration, validity and renewal

An Ethics Committee constituted under rule 7 applies to the Central Licencing Authority in Form CT-01, with the documents listed in Table 1 of the Third Schedule, under rule 8. The Authority may reject the application, with reasons recorded in writing, within forty-five working days of receipt. If no communication is received in that period, registration is deemed to have been granted.

Registration is granted in Form CT-02 and is valid for five years from issue unless suspended or cancelled. Renewal is applied for in Form CT-01 ninety days before expiry, and an application received by then keeps the existing registration in force until the Authority decides.

Any change in membership or constitution must be notified in writing within thirty working days. A rejection may be appealed to the Central Government within sixty working days, and the appeal is disposed of within sixty working days.

What it has to do once registered

A registered Ethics Committee approves protocols before a trial starts at its site, oversees the trial, reviews safety reports and keeps minuted records, under rules 11, 12 and 13. Members follow the Rules and other regulatory requirements, together with the Good Clinical Practices Guidelines formulated by the Central Drugs Standard Control Organisation and adopted by the Drugs Technical Advisory Board, to safeguard the rights, safety and well-being of trial subjects.

A committee whose registration is suspended or cancelled under rule 14 cannot oversee trials, so its status is a live dependency for every sponsor using that site.

Permission to run a clinical trial

There are three routes to clinical trial permission, each with a different response period for the Central Licencing Authority. Every clinical trial application is made under rule 21 in Form CT-04, and every route carries a deemed-approval provision, so silence has a defined legal meaning.

The standard route

On the standard route the Central Licencing Authority has ninety working days to grant permission in Form CT-06, reject the application or communicate deficiencies, under rule 22. If no communication is received in that period, permission is deemed granted and legally valid for all purposes. Under rule 22(2A), inserted in 2022, the applicant then informs the Authority in Form CT-06A before starting, and the record is called deemed approval.

Once deficiencies are rectified, the Authority must grant or reject within ninety days of receiving the required information and documents. After a rejection, the applicant may seek reconsideration within sixty working days on payment of the Sixth Schedule fee, or appeal to the Central Government within forty-five days of receiving the decision.

Drugs discovered or developed in India

Where a drug is discovered in India, or is researched and developed in India and also proposed to be manufactured and marketed here, the Central Licencing Authority must grant, reject or communicate a deficiency within thirty working days of receipt, under rule 23.

If no communication is received in that period, permission is deemed granted and legally valid for all purposes. Before starting the trial, the applicant informs the Authority in Form CT-4A, which is taken on the official record and called automatic approval of the Central Licencing Authority.

The contrast with the standard route is direct: thirty working days rather than ninety, and an approval with its own name and form.

Drugs already approved in another country

Where the new drug is already approved and marketed in a country specified under rule 101, the Central Licencing Authority has ninety working days from receipt to grant, reject or communicate deficiencies, under rule 24. Silence again means deemed permission.

The applicant informs the Authority in Form CT-06A before starting, and the record is called deemed approval. The Rules therefore use two names for the silence mechanisms: automatic approval under rule 23, filed in Form CT-4A, and deemed approval under rules 22 and 24, filed in Form CT-06A. Sponsors frequently mix them up.

Table 2. The three permission routes

RouteRuleDecision periodIf the Authority says nothingForm to file
Standard22Ninety working daysPermission deemed granted, called deemed approvalGranted in Form CT-06; if deemed, inform in Form CT-06A
Discovered or developed in India23Thirty working daysPermission deemed granted, called automatic approvalInform in Form CT-4A
Already approved outside India24Ninety working daysPermission deemed granted, called deemed approvalInform in Form CT-06A

What a permission obliges you to do

A trial at each site may start only after the Ethics Committee of that site, registered under rule 8, has approved the protocol and related documents, under rule 25. A site without its own committee may rely on the committee of another trial site or an independent Ethics Committee constituted under rule 7, which then becomes responsible for the study at that site.

The approving Ethics Committee and the trial site, or the bioavailability and bioequivalence centre, must be in the same city or within a radius of 50 kilometres of the site.

The Central Licencing Authority must be informed of an Ethics Committee approval within fifteen working days of it being granted.

A protocol rejected by a site committee is reported to the Authority before another committee is approached. The trial must be registered with the Clinical Trials Registry of India, maintained by the Indian Council of Medical Research, before the first trial subject is enrolled. The trial follows the approved protocol, and the sponsor and investigator must maintain the integrity of the trial data.

How long a permission lasts

A permission to initiate a clinical trial is valid for two years from the date of issue, unless the Central Licencing Authority extends it, under rule 26. This covers permission in Form CT-06 under rule 22 and automatic approval in Form CT-4A under rule 23. The clock runs from issue, not from first enrolment, so a slow site start-up consumes validity.

Bioavailability and bioequivalence studies

Bioavailability and bioequivalence studies run on a parallel set of forms: the application for permission is made in Form CT-05 and permission is granted in Form CT-07, under rules 31 to 38. The study centre must itself be registered under rules 44 to 51: application in Form CT-08, registration in Form CT-09.

The Rules define a bioavailability study as one assessing the rate and extent to which a drug is absorbed from a formulation and becomes available in the systemic circulation, or at the site of action. A bioequivalence study establishes the absence of a statistically significant difference in the rate and extent of absorption of an active ingredient compared with a reference formulation with the same active ingredient, given in the same molar dose under similar conditions.

Ethics Committee oversight, compensation and medical management obligations apply to these studies as to clinical trials.

Post-trial access

The sponsor must provide post-trial access to the drug free of cost where the investigator recommends it after the trial and the Ethics Committee approves, under rule 27. Two conditions attach: no alternative therapy is available for the indication, and the investigator has found the drug beneficial to that trial subject. The trial subject, or legal heir, must consent in writing.

The investigator certifies, and the trial subject or legal heir declares in writing, that the sponsor has no liability for post-trial use. Those two decisions trigger the obligation; it is not automatic, and once both are made the sponsor has no discretion.

Academic trials that need no permission

An academic clinical trial needs no permission from the Central Licencing Authority where four conditions all hold, under rule 28: the trial is of a permitted drug formulation, solely for academic research into a new indication, route of administration, dose or dosage form; it was initiated after prior Ethics Committee approval; its observations need not be submitted to the Authority; and they are not used for promotional purposes.

The Rules define an academic clinical trial as one of a drug already approved for a certain claim, initiated by an investigator, academic or research institution for a new indication, route, dose or dosage form, with results meant only for academic or research purposes and not for marketing approval.

Where an academic trial may overlap with a clinical trial, the Ethics Committee informs the Authority in writing within thirty working days of receiving the application. The Authority clarifies in writing within thirty working days, and if it does not, no permission is presumed to be required. It then follows the ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.

Compensation, medical management and injury

Where a trial subject dies during a clinical trial or a bioavailability or bioequivalence study, the sponsor, or its representative that obtained the permission, must compensate the legal heir under rule 39, following the procedure in rule 42. Permanent disability or any other injury is compensated by the same party in the same way. Where the injury is not permanent, the quantum is commensurate with the trial subject’s loss of wages, as provided in the Seventh Schedule. The sponsor gives an undertaking to compensate with the trial application.

Compensation is in addition to the cost of medical management. They are separate obligations, often misread as one.

Under rule 40, where an injury occurs the sponsor must provide free medical management for as long as the investigator considers it necessary, or until it is established that the injury is not related to the study, whichever is earlier. If the sponsor fails to provide either, the Authority may, after a hearing, suspend or cancel the study, restrict the sponsor from further studies or take other appropriate action.

Rule 41 sets out when an injury, death or permanent disability is considered related to the study, and the method for determining the amount sits in rule 42 and the Seventh Schedule. Regulatory support can cover the undertaking.

The forms, and what each one is for

The Rules prescribe a numbered series of CT forms. Applications and the permissions answering them carry different numbers, and two forms exist only to record a deemed outcome. The printed text is inconsistent about the zero in form numbers and shows both CT-04 and CT-4 for the same form.

Table 3. The forms

FormWhat it is forRule
CT-01Application for registration, and for renewal, of an ethics committee8, 10, 17
CT-02Registration certificate of an ethics committee for clinical trial and BA/BE study8, 9
CT-03Registration of an ethics committee for biomedical and health research17
CT-04Application for permission to conduct a clinical trial21
CT-4AIntimation to the Authority before starting a trial under automatic approval23
CT-05Application for permission to conduct a bioavailability or bioequivalence study33
CT-06Permission to conduct a clinical trial22
CT-06AIntimation to the Authority before starting a trial under deemed approval22, 24
CT-07Permission to conduct a bioavailability or bioequivalence study34
CT-08Application for registration of a bioavailability and bioequivalence study centre45
CT-09Registration of a bioavailability and bioequivalence study centre47
CT-10Application for permission to manufacture a new drug or investigational new drug for trial, study or examination, test and analysis52
CT-11Permission to manufacture a new drug or investigational new drug53
CT-12 and CT-13Application for permission to manufacture an unapproved active pharmaceutical ingredient59
CT-14 and CT-15Permission to manufacture an unapproved active pharmaceutical ingredient60
CT-16Application for import of a new drug or investigational new drug67

Every statutory clock in one place

The Rules run on working days rather than calendar days almost everywhere, and several periods carry a deemed outcome if the regulator does not respond. Serious adverse event periods run in calendar days instead, as the SAE reporting timelines guide explains.

Table 4. The statutory clocks

What is being timedPeriodRuleIf the period expires
Decision on ethics committee registrationForty-five working days8Registration deemed granted
Validity of ethics committee registrationFive years9Renewal required
Applying to renew ethics committee registrationNinety days before expiry10Existing registration continues until decided
Notifying a change in ethics committee membershipThirty working days12Obligation breached
Decision on a clinical trial application, standard routeNinety working days22Permission deemed granted, file Form CT-06A
Decision where the drug is discovered or developed in IndiaThirty working days23Permission deemed granted, file Form CT-4A
Decision where the drug is approved outside IndiaNinety working days24Permission deemed granted, file Form CT-06A
Informing the Authority of an ethics committee approvalFifteen working days25Condition of permission breached
Validity of permission to initiate a clinical trialTwo years26Extension required
Ethics committee reporting a possible academic trial overlapThirty working days28Obligation breached
Authority responding on an academic trial overlapThirty working days28No permission presumed to be required
Requesting reconsideration after a rejectionSixty working days22Right lapses
Appealing a rejection to the Central GovernmentForty-five days22Right lapses

What changed in 2026

The Rules were amended by G.S.R. 46(E), dated 20 January 2026. It introduces prior intimation in place of permission from the Central Drugs Standard Control Organisation for manufacturing certain categories of drugs, other than certain high-risk categories, for analytical and non-clinical testing. Its stated effect is to remove the test licence requirement for small quantities intended for examination, research or analysis.

Separately, on 21 January 2026 the Central Government notified the replacement of the permission system with an online intimation mechanism for bioavailability and bioequivalence studies of unapproved drugs intended for export. Both changes were described by the Ministry of Health and Family Welfare in a press release of 27 March 2026, in a written reply in the Lok Sabha.

The Rules are amended from time to time, and this article states the position as at the date shown in the closing section.

Questions sponsors ask about the NDCT Rules

What are the New Drugs and Clinical Trials Rules, 2019?

The Indian regulations governing clinical trials, bioavailability and bioequivalence studies, new drugs and investigational new drugs, together with the ethics committees overseeing them. They were notified on 19 March 2019 as G.S.R. 227(E), made under sections 12 and 33 of the Drugs and Cosmetics Act, 1940.

Who is the Central Licencing Authority?

The Rules define it as the Drugs Controller, India, referred to in rule 3. It grants and cancels the permissions and registrations made under the Rules. Chapter II also provides for the delegation of its powers and for a Controlling Officer.

How long does CDSCO take to approve a clinical trial application?

It depends on the route: ninety working days on the standard route under rule 22, thirty working days under rule 23 for drugs discovered or developed in India and ninety working days under rule 24 for drugs already approved in a country specified under rule 101.

What happens if CDSCO does not respond to a clinical trial application?

Permission is deemed granted and legally valid for all purposes. Under rule 23 the applicant files Form CT-4A before starting the trial, and the Rules call this automatic approval. Under rules 22 and 24 the applicant files Form CT-06A, and the Rules call this deemed approval.

How many members must an ethics committee have?

At least seven, from medical, non-medical, scientific and non-scientific areas, including a lay person, a woman member, a legal expert and an independent member. At least half must be unaffiliated with the host institution, and the Chairperson must be one of them.

How long is ethics committee registration valid?

Five years from the issue of Form CT-02, unless suspended or cancelled. Renewal is applied for in Form CT-01 ninety days before expiry, and an application received in time keeps the existing registration in force until the Central Licencing Authority decides.

Does an academic clinical trial need CDSCO permission?

Not where four conditions are met: the trial is of a permitted drug formulation, solely for academic research into a new indication, route, dose or dosage form; the Ethics Committee approved it first; the observations need not be submitted to the Authority; and they are not used for promotion.

What compensation must a sponsor pay if a trial subject is injured?

Financial compensation to the trial subject, or the legal heir after a death, under rule 42. It is additional to free medical management for as long as the investigator considers necessary. For a non-permanent injury the amount follows loss of wages under the Seventh Schedule.

How far can an ethics committee be from the trial site?

The approving Ethics Committee and the clinical trial site, or the bioavailability and bioequivalence centre, must be in the same city or within a radius of 50 kilometres, including where a site relies on another site’s committee or an independent one.

What did the 2026 amendment to the NDCT Rules change?

G.S.R. 46(E) of 20 January 2026 replaced CDSCO permission with prior intimation for manufacturing certain drugs, other than certain high-risk categories, for analytical and non-clinical testing. It removes the test licence requirement for small quantities intended for examination, research or analysis.

About this guide

This guide is based on the gazette text of the New Drugs and Clinical Trials Rules, 2019, published by the Central Drugs Standard Control Organisation, and the Ministry of Health and Family Welfare press release of 27 March 2026. Written by Sahithya K; reviewed by Divya Chandradhara. It states the position as at 29 October 2026 and is reviewed every six months and after any amendment. BioAgile’s certifications and registrations are listed separately.